Is Soni Medicare overvalued or undervalued?

As of 1 July 2025, Soni Medicare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company appears to be overvalued, particularly when considering its negative PE ratio of -21.54, a high Price to Book Value of 16.70, and an EV to EBITDA ratio of 24.04. In comparison to peers, Max Healthcare is categorized as very expensive with a PE of 109.83, while Apollo Hospitals, which is also attractive, has a PE of 74.52.
Despite the recent stock performance showing a significant 96.12% return over the past year compared to the Sensex's 5.31%, the current valuation metrics suggest that Soni Medicare may not be justified at its current price of 50.50. Given the high ratios and the peer comparison, it is prudent to consider Soni Medicare as overvalued in the current market context.